Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ormeloxifene - Central Drug Research Institute

Drug Profile

Ormeloxifene - Central Drug Research Institute

Alternative Names: Centchroman; Centron; Chhaya; Choice-7; Novex; Novex-DS; Saheli; Sevista; Tatkal-72

Latest Information Update: 02 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Central Drug Research Institute
  • Developer Hindustan Latex
  • Class Chromans; Contraceptives; Pyrrolidines; Small molecules
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Metrorrhagia; Pregnancy
  • Phase II Breast cancer

Most Recent Events

  • 31 Dec 2006 Early research in Metrorrhagia in India (PO)
  • 16 Jul 2001 A study in volunteers has been added to the adverse events and pharmacokinetics sections
  • 28 May 1998 A study in patients with breast cancer has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top